Celltrion Inc., of Incheon, South Korea, reported clinical experience of its biosimilar infliximab in 78 inflammatory bowel disease patients at Digestive Disease Week in Washington, showing that treatment is comparable to the reference product, Remicade (Johnson & Johnson), in terms of efficacy and safety.